<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word">
<head>
<meta name="x-apple-disable-message-reformatting" />
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=5" />
<meta name="format-detection" content="telephone=no" />
<meta name="format-detection" content="date=no" />
<meta name="format-detection" content="address=no" />
<meta name="format-detection" content="email=no" />
<!-- <meta name="color-scheme" content="light dark">
<meta name="supported-color-schemes" content="light dark"> -->
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<!-- Disable auto-scale in iOS 10 Mail entirely -->
<style>
body, tr, td, span, div, p, a, li {
	-moz-text-size-adjust: 100% !important;
	-webkit-text-size-adjust: 100% !important;
	margin: 0px !important;
	-ms-text-size-adjust: 100% !important;
	white-space: wrap;
}
/* Pill Buttons CTA Fix for Android Mail and Gmail on Dark Mode */
.btnCTA {
	border-color: #008299 !important;
}
.em_defaultlink a {
	color: inherit;
	text-decoration: none;
}
img + div {
	display: none !important;
}
.userPhotoWidth60 img {
	width: 90px!important;
	max-width: 90px!important;
	min-width: 90px!important;
	height: auto!important;
}
/* .pink{
  color:magenta;
} */

.block_hide{
  display: none !important;
}

@media only screen and (max-width: 375px) {
  .banner_img{
  max-width: 308px !important;
}
}


@media only screen and (max-width: 480px) {
body {
	-webkit-text-size-adjust: 100%;
}

.padd_btm{
  padding-bottom: 0px !important;
}

.hide{
  display: none !important;
}

.block_display{
  display: block !important;
}

.banner_img{
  max-width: 308px !important;
}


.container {
	width: 100% !important;
}
.contai{width: 308px !important;max-width: 308px !important;}
.drop {
	display: block !important;
	width: 100% !important;
}
.imgres {
	width: 100% !important;
	height: auto !important;
}

/* .pink{
  color:magenta;
} */
.pt20 {
	padding-top: 20px !important;
}
.paddingLR24 {
	padding-left: 24px !important;
	padding-right: 24px !important;
}

.paddingLR32{
  padding-left: 32px !important;
	padding-right: 32px !important;
}
.p-12_24 {
	padding: 12px 72px 12px 24px !important;
}
.paddingLR20 {
	padding-left: 20px !important;
	padding-right: 20px !important;
}
.pbt24 {
	padding-bottom: 24px !important;
}
.fullwidth {
	width: 100% !important;
}
.stack-column {
	display: block !important;
	max-width: 100% !important;
}
.agncen {
	text-align: center !important;
	align-items: center !important;
	padding-left: 0px !important;
}
.paddingR0 {
	padding-right: 0px !important;
}
.pt112 {
	padding-top: 12px !important;
}
.cta {
	width: 200px !important;
	margin: 0 auto !important;
	padding: 10px 40px !important;
	font-size: 16px !important;
	line-height: 25px !important;
}
.fullTD {
	padding: 5px 0!important;
}
.pt12 {
	padding-bottom: 0px !important;
	padding-top: 12px !important;
}
.font13 {
	padding-right: 20px !important;
	font-size: 13px !important;
}
div[class=mobileonly] {
	display: block !important;
	margin: 0 !important;
	padding: 0 !important;
	overflow: visible !important;
	width: auto !important;
	max-height: inherit !important;
}
div[class=desktoponly] {
	display: none !important;
}
.left-align {
	text-align: left!important;
}
}


</style>
<!--[if (gte mso 9)|(IE)]>
<style>
		sup {font-size:100% !important;}
</style>
<![endif]--> 
<!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
<o:PixelsPerInch>96</o:PixelsPerInch>
</o:OfficeDocumentSettings>
<w:WordDocument>
<w:DontUseAdvancedTypographyReadingMail/>
</w:WordDocument>
</xml><![endif]-->

</head>
<body marginheight="0" marginwidth="0" leftmargin="0" topmargin="0" style="-moz-text-size-adjust:100% !important; padding:0px !important; -webkit-text-size-adjust:100% !important; margin:0px !important; -ms-text-size-adjust:100% !important; white-space: wrap;" yahoo="fix" bgcolor="#fefefe">
<center class="wrapper">
  <table role="presentation" width="100%" border="0" cellspacing="0" cellpadding="0" bgcolor="#fefefe">
    
    <tr>
      <td align="center" valign="top"><!--[if mso | IE]>
                  <table role="presentation" cellpadding="0" cellspacing="0" width="600" border="0" class="container">
                     <tr>
                        <td align="center" valign="top">
                           <![endif]-->
        
        <table role="presentation" width="600" border="0" align="center" cellspacing="0" class="container" cellpadding="0" bgcolor="#fefefe" style="background-color: #fefefe;max-width: 600px;">
          <!-- <tr>
            <td align="center" valign="top" bgcolor="#e6e6e6">
              <table width="600" border="0" cellspacing="0" class="container" cellpadding="0" style="padding: 20px 30px;">
                     <tr>
                        <td align="left" width="10%" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:14px; color:#030304; line-height:16px; padding-top:16px;"><b>From: </b>  </td>
                        <td align="left" width="90%" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:14px; color:#030304; line-height:16px; padding-top:16px;"><span class="pink">Rep Name &lt;email address&gt;</span>  </td>
                       </tr>
                     <tr>
                        <td align="left" width="10%" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:14px; color:#030304; line-height:10px; padding-top:10px;"><b>To: </b>  </td>
                        <td align="left" width="90%" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:14px; color:#030304; line-height:10px; padding-top:10px;"><span class="pink">HCP Name &lt;email address&gt;</span>  </td>
                   
                     </tr>
                     <tr>
                        <td align="left" width="20%" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:14px; color:#030304; line-height:20px; padding-top:16px;"><b>Subject line: </b>  </td>
                        <td align="left" width="80%" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:14px; color:#030304; line-height:20px; padding-top:16px;">1. <span class="pink">[</span>UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> now has streamlined access for Humana Medicare patients<span class="pink">]</span><br>2. <span class="pink">[</span>UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> may be more accessible to patients<span class="pink">]</span><br>3. <span class="pink">[</span>Following up about an important tool detailing access to PAH therapy<span class="pink">]</span> <br>4. <span class="pink">[</span>Find the PAH asset we discussed enclosed<span class="pink">]</span></td>
                   
                     </tr>
                     <tr>
                        <td align="left" width="20%" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:14px; color:#030304; line-height:20px; padding-top:16px;"><b>Pre-header text:</b>  </td>
                        <td align="left" width="80%" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:14px; color:#030304; line-height:20px; padding-top:16px;">1. <span class="pink">[</span>Download the UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> Formulary Resource<span class="pink">]</span><br>2. <span class="pink">[</span>This resource for a PAH medication has useful information for your Humana Medicare patients<span class="pink">]</span><br></td>
                   
                     </tr>
               </table>
            </td>
          </tr> -->
          <!-- START: PREHEADER OPTIONS-->
    <!--[if !mso]><!-->
    <tr>
      <td align="center" valign="top" style="font-size: 0px; line-height: 0px; color: #ffffff;">{{customText[Download the UPTRAVIÂ® Formulary Resource|This resource for a PAH medication has useful information for your Humana Medicare patients|]}} &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; &zwnj; &nbsp; &zwnj; &nbsp; &nbsp; </td>
    </tr>
    <!--<![endif]-->
    <!-- END: PREHEADER OPTIONS-->
          <tr>
            <td align="center" bgcolor="#ffffff"><table role="presentation" width="100%" border="0" cellspacing="0" cellpadding="0" align="center" style="background-color: #ffffff;">
                <tr>
                  <td style="padding-left: 32px;padding-right: 150px;padding-top: 16px;padding-bottom: 16px;" class="p-12_24"><table role="presentation" width="100%" border="0" cellspacing="0" cellpadding="0" align="center" >
                      <tr>
                        <td align="left" valign="top" class="stack-column fullTD" style="font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height: 24px; text-align: left;font-weight: 400; color: #006D80;"><a target="_blank" href="https://www.uptravihcp.com/uptravi-important-safety-information/" style="color: #327e59; text-decoration: underline;" class="font13">Important&nbsp;Safety&nbsp;Information</a></td>
                        <td class="stack-column pt12_header"><table role="presentation" width="100%" border="0" cellspacing="0" cellpadding="0" align="center">
                            <tr>
                              <td valign="top" align="left" style="font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height: 24px; color: #006D80; font-weight: 400; text-align: left;" class="fullTD"><a target="_blank" href="https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/UPTRAVI-pi.pdf" style="color: #327e59;text-decoration: underline;"  class="font13 ">Prescribing&nbsp;Information</a></td>
                              
                            </tr>
                          </table></td>
                      </tr>
                    </table></td>
                </tr>
              </table></td>
          </tr>
          <!-- <tr>
            <td align="center" valign="top"><a href="https://www.tremfyahcp.com/" target="_blank"><img src="./images/banner.png" width="600" alt="TREMFYAÂ® (guselkumab) logo" title="TREMFYAÂ® (guselkumab) logo"  border="0" style="display:block;max-width: 600px;" class="g-img banner_img" /></a></td>
          </tr> -->
          <tr>
            <td align="center" valign="top" style="padding:32px 32px 28px 32px;" class="paddingLR24" bgcolor="#0a6f44">
              <table role="presentation" width="100%" border="0" cellspacing="0" class="container" cellpadding="0">

               

              <!-- <tr>
                <td align="center" valign="top" style="padding-bottom: 25px;"><a style="cursor: none !important;"> <img src="./images/logo.png" width="154" alt="UPTRAVIÂ® (selexipag)" title="UPTRAVIÂ® (selexipag)"  border="0" style="display:block;max-width: 154px;cursor: none !important;" class="g-img" /></a></td>
              </tr> -->

              <tr>
                <td align="center" valign="top" style="color: #ffffff;"><img src="https://cdnae1.vod309.com/2d357e98-afc9-439d-86bc-91b2f5b9f69f/0000000/000000/015/103/0/27/assetFiles/images/images/logo.png" width="275" alt="UPTRAVIÂ® (selexipag)" title="UPTRAVIÂ® (selexipag)"  border="0" style="display:block;max-width: 275px;" class="g-img" /></a></td>
              </tr>
                <tr>
                  <td align="center" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color: #ffffff; line-height:26px; font-weight: 700;"><a href="#isi"
                    title="Important Safety Information" target="_self"
                    style="color: #ffffff; text-decoration: none;"> Please see Important Safety Information below.</a>
                   </td>
                </tr>
                </table>
                </td>
                </tr>


                <tr>
                  <td align="center" valign="top" style="padding:0px 32px 28px 32px;" class="paddingLR24 ">
                    <table role="presentation" width="100%" border="0" cellspacing="0" class="container" cellpadding="0">
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:20px; color:#030304; line-height:30px; padding-top: 15px;" class="pt112"><strong>Dear {{customText [Dr. |Nurse |Mr. |Mrs. |Ms. |Mx. ]}}{{accLname}},</strong></td>
                      </tr>
                      <tr>
                        <td align="left" class="pt12" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#030304; line-height:26px; padding-top:16px;">{{customText [Thank you for meeting with me. I wanted to follow up with you directly to share the formulary resource for | I enjoyed our conversation. Please find more information below about the formulary flash card for]}} UPTRAVI<sup style="font-size:60%;line-height:0px;vertical-align:6px;mso-line-height-rule:exactly;">&reg;</sup>.</td>
                      </tr>
              </table></td>
          </tr>
          <!-- <tr>
            <td align="left" valign="top" bgcolor="#e6f3f5" style="font-size: 10px; line-height: 12px;"><img src="images/grappa-graphic.png" width="600" alt="Group for Research and Assessment of Psoriasis and Psoriatic Arthritis GRAPPA logo" style="display: block;" border="0" class="imgres g-img" /></td>
          </tr> -->

          <tr>
            <td align="center" valign="top" bgcolor="#e6f1ec" style="background-color:#e6f1ec;">
              <table width="100%" border="0" cellspacing="0">

          
          <tr>
            <td align="center" valign="top" bgcolor="#e6f1ec" class="pt20 paddingLR24" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:24px; color:#006F44; padding:16px 32px 32px 32px; line-height: 34px;text-align: center;"><strong>This UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 8px; mso-line-height-rule: exactly;">&reg;</span> formulary resource may help streamline patient access</strong></td>
          </tr>

          <!-- <tr>
            <td align="center" valign="top" bgcolor="#e6f1ec" style="padding-bottom: 32px;" class="hide"><img src="https://cdnae1.vod309.com/2d357e98-afc9-439d-86bc-91b2f5b9f69f/0000000/000000/015/103/0/27/assetFiles/images/images/content_image_1.jpg" width="200" alt="UPTRAVIÂ® Formulary Resource" title="UPTRAVIÂ® Formulary Resource"  border="0" style="display:block;max-width: 536px;" class="g-img " /></td>
            
          </tr> -->
          <tr>
            <td align="center" valign="top" bgcolor="#e6f1ec" style="padding-bottom: 32px;padding-left: 32px;padding-right: 32px;" class=""><img src="images/Image1.png" width="536" alt="UPTRAVIÂ® Formulary Resource" title="UPTRAVIÂ® Formulary Resource"  border="0" style="display:block;max-width: 536px;" class="g-img contai " /></td>
            
          </tr>

          <!-- <tr>
            <td align="center" valign="top" bgcolor="#e6f1ec" style="padding-bottom: 32px; align-text:center" class="block_hide block_display"><img src="https://cdnae1.vod309.com/2d357e98-afc9-439d-86bc-91b2f5b9f69f/0000000/000000/015/103/0/27/assetFiles/images/images/content_image_1.jpg" width="150" alt="UPTRAVIÂ® Formulary Resource" title="UPTRAVIÂ® Formulary Resource"  border="0" style="display:block;max-width: 308px;" class="g-img" /></td>
            
          </tr> -->
 
          <tr>
            <td align="center" valign="top" bgcolor="#e6f1ec" class="pt112 paddingLR24" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding:0px 32px 32px 32px;text-align: center;">This informative asset contains useful information on formulary updates for UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span>. These changes may help your patients access UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> under a Humana Medicare plan.</td>
          </tr>

           <!--BEGIN CTA rounded-->

            <tr>
              <td align="center" valign="top" bgcolor="#e6f1ec"><a href="https://www.cam-assets.janssen.com/UPTRAVI_Humana_Announcement.pdf" target="_blank"><img src="https://cdnae1.vod309.com/2d357e98-afc9-439d-86bc-91b2f5b9f69f/0000000/000000/015/103/0/27/assetFiles/images/images/cta.png" width="226" alt="Download the resource" title="Download the resource"  border="0" style="display:block;max-width: 226px;" class="g-img "/></a></td>
              
            </tr>
            <!--END CTA rounded-->

            <tr>
              <td height="20" align="left" valign="top" style="line-height: 0px; font-size: 0px;" bgcolor="#e6f1ec">&nbsp;</td>
            </tr>

            </table>
            </td>
            </tr>

          
          
          
          <tr>
            <td align="center" valign="top" bgcolor="#E6F3F5"><table width="100%" border="0" cellspacing="0" class="container" cellpadding="0" role="presentation">
                <tr>
                  <td align="center" valign="top"  style="padding-top:16px;padding-left:31px;padding-right:32px;padding-bottom:24px;background-color: #ffffff;" class="paddingLR24"><table width="100%" border="0" cellspacing="0" class="container" cellpadding="0" role="presentation">
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:20px; color:#006F44;padding-bottom: 12px; line-height:30px;"><strong>INDICATIONS</strong></td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333;padding-bottom: 12px; line-height:26px;">UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.</td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333;padding-bottom: 12px; line-height:26px;">Effectiveness of UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> Tablets was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms.</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;">Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), and PAH associated with congenital heart disease with repaired shunts (10%).</td>
                      </tr>
                      <tr>
                        <td align="left"  valign="top" id="isi" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:20px; color:#006f44; line-height:30px;padding-top:30px;"><a name="isi"></a><strong>IMPORTANT SAFETY INFORMATION</strong></td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:18px; color:#006f44; line-height:28px;padding:30px 0px 0px 0px;"><strong>CONTRAINDICATIONS</strong></td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 12px;">Concomitant use of strong inhibitors of CYP2C8 (eg, gemfibrozil) with UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> is contraindicated.</td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;">Hypersensitivity to the active substance or to any of the excipients is contraindicated.</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:18px; color:#006f44; line-height:28px;padding:16px 0px 0px 0px;"><strong>WARNINGS AND PRECAUTIONS</strong></td>
                      </tr>
                     
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;"><strong>Pulmonary Edema with Pulmonary Veno-Occlusive Disease (PVOD)</strong> <br>Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span>.</td>
                      </tr>
                      
                        
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:18px; color:#006f44;font-weight:700; line-height:28px;padding-bottom:0px;padding-top: 16px;">ADVERSE REACTIONS</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;padding-bottom: 12px;">Adverse reactions more frequent compared to placebo (â¥3%) seen with UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> Tablets are headache (65% vs 32%), diarrhea (42% vs 18%), jaw pain (26% vs 6%), nausea (33% vs 18%), myalgia (16% vs 6%), vomiting (18% vs 9%), pain in extremity (17% vs 8%), flushing <br style="display: block;" class="hide">(12% vs 5%), arthralgia (11% vs 8%), anemia (8% vs 5%), decreased appetite (6% vs 3%), and rash (11% vs 8%).</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;padding-bottom: 12px;">These adverse reactions are more frequent during the dose titration phase.</td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;padding-bottom: 8px;">Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> Tablets and in none of the patients on placebo.
                          </td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:18px; color:#006f44; line-height:28px;padding:16px 0px 0px 0px;"><strong>DRUG INTERACTIONS</strong></td>
                      </tr>
                     
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 0px;padding-top: 5px;"><strong>CYP2C8 Inhibitors</strong></td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;padding-bottom: 12px;">Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant use of UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> with strong inhibitors of CYP2C8 is contraindicated.</td>
                      </tr>

                      

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 12px;">Concomitant administration of UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> with clopidogrel, a moderate inhibitor of CYP2C8, had no relevant effect on the exposure to selexipag and increased the exposure to the active metabolite by approximately 2.7- fold. Reduce the dosing of UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> to once daily in patients on a moderate CYP2C8 inhibitor.
                          </td>
                      </tr>

                      
                     
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 0px; padding-top: 12px;"><strong>CYP2C8 Inducers</strong></td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 16px;">Concomitant administration with an inducer of CYP2C8 and UGT 1A3 and 2B7 enzymes (rifampin) halved exposure to the active metabolite. Increase UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> dose, up to twice, when co-administered with rifampin. Reduce UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> when rifampin is stopped.
                          </td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:18px; color:#006f44; line-height:28px;padding:0px 0px 5px 0px;"><strong>DOSAGE AND ADMINISTRATION</strong></td>
                      </tr>
                     
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 0px;"><strong>Recommended Dosage</strong></td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;padding-bottom: 12px;">Recommended starting dose is 200 mcg twice daily for UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> Tablets. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If dose is not tolerated, reduce to the previous tolerated dose.</td>
                      </tr>

                      
                     
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 0px; padding-top: 12px;"><strong>Patients With Hepatic Impairment</strong></td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 12px;">For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose of UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> Tablets is 200 mcg <span style="text-decoration: underline;">once daily</span>. Increase by 200 mcg <span style="text-decoration: underline;">once daily</span> at weekly intervals, as tolerated. Avoid use of UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> in patients with severe hepatic impairment (Child-Pugh class C).
                          </td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 0px; padding-top: 12px;"><strong>Co-administration With Moderate CYP2C8 Inhibitors</strong></td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 12px;">When co-administered with moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox and teriflunomide), reduce the dosing of UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> to <span style="text-decoration: underline;">once daily</span>.
                          </td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 0px; padding-top: 12px;"><strong>Dosage Strengths</strong></td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 12px;">UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> tablet strengths:<br> 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg.
                          </td>
                      </tr>



                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:18px; color:#006f44; line-height:28px;padding:12px 0px 0px 0px;"><strong>Additional Important Safety Information for UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 6px; mso-line-height-rule: exactly;">&reg;</span> IV</strong></td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;padding-bottom: 12px;">Use UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> for injection in patients who are temporarily unable to take oral therapy.</td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 12px;">Administer UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> for injection twice daily by intravenous infusion at a dose that corresponds to the patient's current dose of UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> Tablets (see Table 1 in full Prescribing Information). Administer UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> for injection as an 80-minute intravenous infusion.
                          </td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 12px; padding-top: 12px;"><strong>Adverse Reactions:</strong> Infusion-site reactions (infusion-site erythema/redness, pain and swelling) were reported with UPTRAVI<span style="font-size: 65%; line-height: 0px; vertical-align: 5px; mso-line-height-rule: exactly;">&reg;</span> for injection.</td>
                      </tr>

                    

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 12px; padding-top: 12px;font-weight: bold;">Please see full <a style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; color: #006f44;text-decoration: underline;" href="https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/UPTRAVI-pi.pdf" target="_blank">Prescribing&nbsp;Information</a>.</td>
                      </tr>

                      
                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px; padding-bottom: 12px;">cp-126160v5</td>
                      </tr>

                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;">PAH=pulmonary arterial hypertension.</td>
                      </tr>

                      <tr>
                        <td height="20" align="left" valign="top" style="line-height: 0px; font-size: 0px; border-bottom: 1px solid #C3CCD5" bgcolor="ffffff">&nbsp;</td>
                      </tr>

                      <tr>
                        <td height="20" align="left" valign="top" style="line-height: 0px; font-size: 0px;" bgcolor="ffffff">&nbsp;</td>
                      </tr>


                      <tr>
                        <td align="left" valign="top" style="font-family:Arial, Helvetica, sans-serif;mso-line-height-rule: exactly; font-size:16px; color:#333333; line-height:26px;">
                          I look forward to following up with you at our next meeting.</td>
                      </tr>
                    </table></td>
                </tr>
                
                
                <tr>
                  <td align="center" valign="top" bgcolor="#fefefe" style="padding: 12px 32px;"><table width="100%" border="0" cellpadding="0" cellspacing="0" role="presentation">
                      <tr>
                        <td style="mso-line-height-rule: exactly; font-family: Arial, Helvetica, sans-serif; font-size: 16px; line-height: 26px; color: #333333; padding-left: 0px;padding-bottom: 12px; " valign="top"><strong>Warm regards,Â </strong></td>
                      </tr>
                      <tr>
                        <td style="mso-line-height-rule: exactly; font-family: Arial, Helvetica, sans-serif; font-size: 16px; line-height: 26px; color: #333333;" valign="top">
                          
                          <a href="tel:{{userName}}"  target="_blank" style="font-family: Arial, Helvetica, 'sans-serif'; color: #333333; font-size: 16px; line-height: 26px; text-decoration: none; display: inline-block;">{{userName}}</a><br> 
                         

                          <a href="tel:{{User.MobilePhone}}"  target="_blank" style="font-family: Arial, Helvetica, 'sans-serif'; color: #333333; font-size: 16px; line-height: 26px; text-decoration: none; display: inline-block;">{{User.Phone}}</a><br>

                          <a href="mailto:{{userEmailAddress}}" target="_blank" style="font-family: Arial, Helvetica, 'sans-serif'; color: #333333; font-size: 16px; line-height: 26px; text-decoration: none; display: inline-block;">{{userEmailAddress}}</a>

                         </td>
                      </tr>
                    </table></td>
                </tr>
                
                <tr>
                  <td valign="top" align="center" style="padding:0px 32px 0;" class="px-24 pt-16" bgcolor="#fefefe"><table width="100%" border="0" cellspacing="0" cellpadding="0" role="presentation">
                      <tr>
                        <td style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 24px; color: #1C1E21;  padding:16px 0 8px 0;"> If you have any questions about the information in this message, please do not hesitate to contact me. </td>
                      </tr>
                      <tr>
                        <td width="100%" style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 24px; color: #1C1E21;  padding: 0 0 8px 0;"> If you do not wish to receive further messages from me, click here to <a href="https://privacyportal.onetrust.com/hosted-webform/consent/96f23ee1-34e3-41d6-8d5a-07f0d554152b/91a13eae-8be7-46b4-8ecb-852071c900b8?UPTRAVI=&Email={{EmailAddressUnsub}}" target="_blank" style="color: #EB1700; text-decoration: underline;  font-family: Arial, Helvetica, sans-serif;"><strong>unsubscribe</strong></a>. </td>
                      </tr>
                      <tr>
                        <td width="100%" style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 24px; color: #1C1E21;  padding: 0 0 8px 0;">You can manage your subscription preferences <a href="https://privacyportal.onetrust.com/ui/#/preferences/multipage/login/caf797c0-90d1-4fe6-85a2-9ea93a621bbb" target="_blank" style="color: #EB1700; text-decoration: underline;  font-family: Arial, Helvetica, sans-serif;"> <strong>here</strong></a>.</td>
                      </tr>
                      <tr>
                        <td style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 24px; color: #1C1E21;  padding: 0 0 8px 0;" class="pb-10">Please click here to read our <a href="https://innovativemedicine.jnj.com/us/privacy-policy" target="_blank" style="color: #EB1700; text-decoration: underline;  font-family: Arial, Helvetica, sans-serif;"><strong>privacy policy</strong></a>. </td>
                      </tr>
                      <tr>
                        <td style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 24px; color: #EB1700;  padding: 0 0 16px 0;" class="pb-10"><a href="https://innovativemedicine.jnj.com/us/legal-notice/" target="_blank" style="color: #EB1700; text-decoration: underline;  font-family: Arial, Helvetica, sans-serif;"><strong>Terms of Use</strong></a></td>
                      </tr>

                      
                      <tr>
                        <td style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 24px; color: #1C1E21;  padding: 0;">Actelion Pharmaceuticals US, Inc., a Johnson &amp; Johnson company</td>
                      </tr>
                      <tr>
                        <td style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 24px; color: #1C1E21;  padding: 0;">11&#xFEFF;25&#xFEFF; &#xFEFF;Tr&#xFEFF;en&#xFEFF;to&#xFEFF;n&#xFEFF;-&#xFEFF;Ha&#xFEFF;rb&#xFEFF;ou&#xFEFF;rt&#xFEFF;on&#xFEFF; &#xFEFF;Ro&#xFEFF;ad&#xFEFF;</td>
                      </tr>
                      <tr>
                        <td style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 24px; color: #1C1E21;  padding: 0;">&#xFEFF;Ti&#xFEFF;tu&#xFEFF;sv&#xFEFF;il&#xFEFF;le,&#xFEFF; &#xFEFF;NJ&#xFEFF; &#xFEFF;0&#xFEFF;8&#xFEFF;5&#xFEFF;6&#xFEFF;0&#xFEFF;</td>
                      </tr>
                    </table></td>
                </tr>
                <tr>
                  <td valign="top" align="center" style="padding: 16px 32px 0;" class="px-24 pt-12" bgcolor="#fefefe"><table width="100%" border="0" cellspacing="0" cellpadding="0" role="presentation">
                      <tr>
                        <td align="left" style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 24px; color: #1C1E21; font-weight: 400; padding: 0 0 12px 0;" class="p-0 stack-column">&copy; Johnson &amp; Johnson and its affiliates 2025 </td>
                        <td align="right"  style="font-family: Arial, Helvetica, sans-serif; font-size: 14px; line-height: 20px; color: #1C1E21; font-weight: 400; padding: 0 0 12px 0;" class="stack-column left-align" > 07/&#xFEFF;25 &nbsp; cp-5&#xFEFF;1&#xFEFF;9&#xFEFF;3&#xFEFF;7&#xFEFF;9&#xFEFF;v&#xFEFF;1&#xFEFF;</td>
                      </tr>
                      <tr>
                        <td valign="top" align="center" style="padding: 0 0px 32px 0px;" class="px-24" bgcolor="#fefefe"><table width="100%" border="0" cellspacing="0" cellpadding="0" role="presentation">
                            <tr>
                              <td align="left"><img src="https://cdnae1.vod309.com/2d357e98-afc9-439d-86bc-91b2f5b9f69f/0000000/000000/015/103/0/27/assetFiles/images/images/footer-logo.png" alt="" width="236" style="display: block" border="0" /></td>
                            </tr>
                            <tr>
                              <td height="35" align="left" valign="top" style="line-height: 0px; font-size: 0px;">&nbsp;</td>
                            </tr>
                          </table></td>
                      </tr>
                    </table></td>
                </tr>
              </table>
              
              <!--[if mso | IE]> 
                              </td>
                           </tr>
                        </table>
                        <![endif]--></td>
          </tr>
        </table></td>
    </tr>
  </table>
</center>
</body>
</html>